

J&J at AANEM and MGFA 2024

Data presentation highlights: MGFA Special Session – October 15

**Indicates also being presented as a poster at AANEM (Oct. 16-18)*

Presenter/Presentation Time (ET) Poster Number	Abstract Name
Oral Session	
Jonathan Strober, M.D. 10:24-10:31am* (MG100)	Safety and effectiveness of nipocalimab in adolescent participants in the open label Phase 2/3 Vibrance-MG clinical study
Tuan Vu, M.D. 10:38-10:45am* (MG102)	Efficacy and safety of nipocalimab in patients with generalized myasthenia gravis: topline results from the double-blind, placebo-controlled, randomized Phase 3 Vivacity-MG3 study
Sheng Gao, BS 11:32-11:39am* (MG111)	Post-hoc analysis of clinically relevant anti-vaccine antibodies in participants treated with nipocalimab
Poster Session	
MG2	Disease burden in patients with generalized myasthenia gravis
MG3	Partnering with patients and caregivers to guide the development of impactful study engagement tools in a generalized myasthenia gravis real world study
MG16*	Leveraging AI to characterize mental health experiences throughout the myasthenia gravis diagnosis journey
MG17	Uncontrolled myasthenia gravis can contribute to additional stress burden and adverse mental health experiences
MG18	Sentiment analysis of digital conversations related to myasthenia gravis by race/ethnicity
MG19	A randomized, open-label study on the effect of nipocalimab on vaccine responses in healthy participants
MG24	Long-Term Safety and Efficacy Of Nipocalimab In Generalized Myasthenia Gravis: Vivacity-Mg3 Open-Label Interim Analysis
MG25	Symptom severity assessment using MG-ADL items and domains in a 24-week, Phase 3 study (Vivacity) of nipocalimab in gMG
MG78*	Assessing the suitability of the NeuroQoL Fatigue to evaluate fatigue in patients living with gMG
MG45*	Factors influencing exacerbations and crises in gMG: findings from a claims database study
MG46	Impact of race and social determinants of health on exacerbations in generalized myasthenia gravis
MG93*	Perinatal treatment patterns in myasthenia gravis

MG94*	Adverse pregnancy outcomes in myasthenia gravis: A retrospective cohort study in a US health insurance claims database
-------	--

Data presentation highlights: AANEM-only – October 16-18

Poster Number	Abstract Name
Poster Session	
MyReg RWE (#143)	Treatment outcomes among patients with generalized myasthenia gravis in the Czech Republic: results from MYasthenia gravis REGistry (MyReg)
MG-REST Canada (#256)	Interim results for myasthenia gravis-resource utilization, epidemiology, survival & treatment patterns (MG-REST) study in Ontario, Canada